Trial Profile

A clinical phase 3 study of Zigakibart in China

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zigakibart (Primary)
Indications IgA nephropathy
Focus Therapeutic Use

Most Recent Events

10 Jan 2024 New trial record
05 Jan 2024 According to SanReno Therapeutics media release, company obtained approval from China CDE for entry into the Phase 3 study in Oct 2023.
05 Jan 2024 According to SanReno Therapeutics media release, company today announces its acquisition by Novartis. Also, in late 2021 as a joint venture between the investor consortium and Chinook Therapeutics (now part of Novartis).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com